Entasis Therapeutics

Entasis is a clinical-stage biopharmaceutical company engaged in the research, development, and commercialization of novel antibacterial products, focusing on treating serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design and development platform has produced a series of candidate products, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and ETX0462 (targeting Pseudomonas infections).